Abstract
Objective: To assess the cost-efficacy of three fixed-combination glaucoma treatments currently available in Spain [bimatoprost with timolol (BT)-Ganfort®, latanoprost with timolol (LT)- Xalacom®, and travoprost with timolol (TT)- DuoTrav®]. Methods: Because no studies are available that give a direct comparison of these drugs, a systematic review was carried out to assess their efficacy. Resource consumption and costs were estimated using a model of usual local practice. For each of the three drugs, average and incremental cost-efficacy ratios were determined in terms of euros per percentage point of reduction of intraocular pressure (IOP) over a three-month period. Results: BT reduced IOP by 35.1%, LT by 35.0% and TT by 34.7%. Average cost-efficacy was estimated to be € 5.34 per percentage point of IOP reduction with BT, € 5.40 with LT, and € 5.45 with TT. Incremental cost-efficacy (incremental cost per incremental percentage point of IOP reduction) was estimated to be € 94.65 for LT vs. TT, and was negative for BT vs. TT and BT vs. LT, since in both cases BT was more efficacious and less expensive. Conclusions: Compared to travoprost/timolol and latanoprost/timolol, bimatoprost/timolol appears to be the most economic alternative, with equal or better efficacy and safety results.
| Original language | English |
|---|---|
| Pages (from-to) | 595-600 |
| Journal | Archivos de la Sociedad Espanola de Oftalmologia |
| Volume | 83 |
| Issue number | 10 |
| Publication status | Published - 1 Oct 2008 |
Keywords
- Beta-blocker
- Cost analysis
- Fixed combinations
- Glaucoma
- Prostaglandin analogue